Sapanisertib
- Generic Name
- Sapanisertib
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15N7O
- CAS Number
- 1224844-38-5
- Unique Ingredient Identifier
- JGH0DF1U03
- Background
Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
- Conditions
- Malignant Neoplasms of Digestive OrgansMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Lip Oral Cavity and PharynxMalignant Neoplasms of Male Genital Organs
- Interventions
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02812056
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 141
- Registration Number
- NCT02756364
- Locations
- 🇺🇸
New England Cancer Specialists, Scarborough, Maine, United States
🇺🇸Texas Oncology, P.A., Dallas, Texas, United States
🇺🇸St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States
Phase II Study of TAK228 in Relapsed Lymphoma
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02727777
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
- Conditions
- Clear-cell Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT02724020
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy
🇫🇷Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, Paris, France
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
- Conditions
- Endometrial Neoplasms
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 241
- Registration Number
- NCT02725268
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸University of Kansas Medical Center Research Institute, Inc., Westwood, Kansas, United States
🇺🇸University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
- Conditions
- Metastatic Breast CancerSolid Tumors
- Interventions
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 47
- Registration Number
- NCT02719691
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Gary Schwartz
- Registration Number
- NCT02619669
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
- Conditions
- High Grade SarcomaRecurrent Malignant Peripheral Nerve Sheath TumorMetastatic Undifferentiated Pleomorphic SarcomaStage III Uterine Corpus Leiomyosarcoma AJCC v8Metastatic LeiomyosarcomaRecurrent Synovial SarcomaRecurrent Undifferentiated Pleomorphic SarcomaStage IVA Uterine Corpus Leiomyosarcoma AJCC v8Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8Metastatic Malignant Peripheral Nerve Sheath Tumor
- Interventions
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 151
- Registration Number
- NCT02601209
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
- Conditions
- Hepatocellular CarcinomaLiver CancerHCC
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 11
- Registration Number
- NCT02575339
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT02514824
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.